Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mechanism and Predictors of Cardiotoxicity After Prostate Cancer Treatment: A Parallel Cohort and Randomized Trial Comparing Radiation Alone, Radiation Plus Leuprolide, and Radiation Plus Relugolix

NCT05320406 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT05320406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05320406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mechanism and Predictors of Cardiotoxicity After Prostate Cancer Treatment: A Parallel Cohort and Randomized Trial Comparing Radiation Alone, Radiation Plus Leuprolide, and Radiation Plus Relugolix
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 6, 2022
Completion date
October 30, 2026
Enrollment
94 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

biochemically recurrent prostate carcinoma, localized prostate carcinoma, stage i prostate cancer ajcc v8, stage ii prostate cancer ajcc v8, stage iia prostate cancer ajcc v8, stage iib prostate cancer ajcc v8, stage iic prostate cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iiia prostate cancer ajcc v8, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8